Search

everythinglearnresearchcommunity

for

Search:↓

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.

A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.

A user shares their hair loss treatment regimen, which includes oral finasteride, oral and topical minoxidil, RU58841, LLLT cap, microneedling, ketoconazole shampoo, biotin, vitamin D3, NAC supplement, MK677, collagen, and other hair care products. They seek opinions on its effectiveness.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in hair cloning technology.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.

Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hair follicle stem cells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

Bovine colostrum is being discussed for its potential in hair regeneration, with some users noting that oral consumption may not be effective due to stomach acid destroying exosomes. The conversation also touches on ethical concerns about sourcing colostrum.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

The user asked for opinions on a hair loss treatment involving PRP and Exosomes. They recently tried this treatment.

User started minoxidil, noticed forehead lines and dark circles, and asked for non-invasive skin aging prevention methods. Another user suggested using tretinoin and hyaluronic acid for long-term benefits.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

The conversation is about a hair loss treatment regimen using high concentrations of natural ingredients: pumpkin seed oil, saw palmetto, rosemary and peppermint essential oils, and caffeine. The user also practices microneedling, scalp massage, and takes Nutrafol.

The user shared progress pictures and discussed their hair loss treatment routine, which includes minoxidil, finasteride, Nizoral, dermastamping, tretinoin, rosemary oil, hair peptides, biotin, and collagen supplements. They are seeking advice on hair transplantation, minoxidil application, and the impact of testosterone replacement therapy on hair loss.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The regimen for hair loss includes topical finasteride, clascoterone, tretinoin, minoxidil, oral saw palmetto, beta-sitosterol, vitamin D, microneedling, and anti-fungal shampoo. Expected benefits are increased hair growth and density, with considerations for potential skin irritation and interactions between treatments.

A user is making a 2-Deoxy-D-ribose solution and asks if it can be put into an oil instead of a gel, considering adding hydrocortisone and retinoic acid. They seek advice on the best carrier oil for hair growth.

A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.